I think that 2014 should be a pretty good year for us. My only concern is their cash position. They are good to mid 2015 but realistically they have to get this somewhat settled by mid 2014. Could have a deal on 5010 by then., which would help.
Blrx set up at the market financing so a pop in the stock would allow them to sell some shares and get enough money to 2016. I think that would give us the room for some of our compounds to settle in, somewhat sticky until that happens.
Investment day next week, maybe something interesting will occur.
There is risk here but with all in the pipeline still seems like a pretty good risk reward bet. Though I don't know her have been told CEO pretty good.
As far as there cash position don't forget that in q1 they are getting the results of there heart drug from Ikaria which would trigger I think around a 40 million dollar payment. Plus then you have possible deals like you said with 5010 and many of there other drug candidates.
I think it is highly unlikely that they will sell additional shares with so many big cash catalysts coming so soon--and I assume that in the next few weeks the interim results on the cancer drug. Unlike the schizophrenia drug there is no hype surrounding this which is good because if results are good the stock should shoot up 50%-100% imo as no one is expecting anything.